Finally talazoparib is a PARP inhibitor currently under investigation as single agent in BRCA mutated breast cancer both in a phase III study in metastatic disease and in a pilot phase II study as neoadjuvant treatment (NCT02282345, https://clinicaltrials.gov/). The gene discussed is PARP1; the disease is breast cancer.